James V. Desiderio
Keine laufenden Positionen mehr
Profil
James V.
Desiderio worked as an Executive Director & Head-Program Management at Idenix Pharmaceuticals LLC, a Principal at Bristol Myers Squibb Co., Gilead Sciences, Inc., and Cubist Pharmaceuticals LLC.
He also served as Senior Vice President-Regulatory & Quality at Acceleron Pharma, Inc. from 2007 to 2021.
Desiderio received his undergraduate degree from Long Island University and his graduate and undergraduate degrees from the College of Veterinary Medicine.
Ehemalige bekannte Positionen von James V. Desiderio
Unternehmen | Position | Ende |
---|---|---|
ACCELERON PHARMA INC. | General Counsel | 01.12.2021 |
CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
IDENIX PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | - |
Ausbildung von James V. Desiderio
Long Island University | Undergraduate Degree |
College of Veterinary Medicine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private Unternehmen | 3 |
---|---|
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |